Assessment of daily maintenance dose of Sifrol®, L-dopa sparing effect, effect on tremor, depression, anhedonia and tolerability
Study Type
OBSERVATIONAL
Enrollment
657
Change in cumulative daily doses of Sifrol®
Changes in the doses between visits are evaluated using Wilcoxon's signed rank test
Time frame: up to 8 weeks
Changes in cumulative daily doses of L-dopa
Changes in the doses between visits are evaluated using Wilcoxon's signed rank test
Time frame: up to 8 weeks
Change from Baseline in Short Parkinson Evaluation Scale (SPES) total score
Time frame: Baseline, after 8 weeks
Change from Baseline in SPES subscales
Psychopathological disturbances, Activities of daily living, Evaluation of motor function, Tremor, Resting Tremor, Postural tremor, Complications of therapy
Time frame: Baseline, after 8 weeks
Change from Baseline in Snaith-Hamilton-Pleasure-Scale total score
patients with SPES depression \>= 2
Time frame: Baseline, after 8 weeks
Change from Baseline in Tremor Impact Scale (TIS-D) total score
Time frame: Baseline, after 8 weeks
Change from Baseline in global Parkinson's Disease (PD) symptoms
Akinesia, anhedonia, depression, dyskinesia, motor fluctuation, cognitive disturbances, rigor and tremor
Time frame: Baseline, after 8 weeks
Global assessment of efficacy by investigator on a 5-point scale
Time frame: after 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Global assessment of tolerability by investigator on a 5-point scale
Time frame: after 8 weeks
Number of patients with adverse events
Time frame: up to 8 weeks
Number of patients with adverse drug reactions
Time frame: up to 8 weeks